Skip to main content
SpringerLink
Log in

Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis

  • Biomarkers of Heart Failure (WH Tang & J Grodin, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

The purpose of this review is to describe the effects of angiotensin receptor neprilysin inhibitor (ARNI) therapy on the natriuretic peptide axis (NPA), with a particular focus on B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and C-type natriuretic peptide (CNP) to better understand the biology behind the improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF).

Recent Findings

BNP, ANP, and CNP are the three main natriuretic peptides (NP); they share a common structure and ultimately mediate their actions by activating cyclic guanosine monophosphate (cGMP). ARNI therapy results in a decrease of N-terminal pro-BNP (NT-proBNP) and increase of BNP levels respectively. It is been questioned whether these changes may result from unique laboratory assays characteristics rather than actual biological implications. It appears to be that the prognostic accuracy of BNP for cardiovascular outcomes remains independent and comparable to that of NT-proBNP while on ARNI therapy. ANP levels also increase with ARNI therapy, but no consistent change has been described for CNP levels. There is evidence that the changes in BNP and NT-proBNP correlate with improvement in echocardiographic parameters of volume and function.

Summary

The dual effect of neprilysin inhibition and angiotensin receptor blockade has substantial implications on the natriuretic peptide axis (NPA). The changes seen in BNP and NT-proBNP specifically have shown to correlate with improvement in echocardiographic parameters. Further results exploring the biologic effects of ARNI therapy on other NPs are still pending and likely will provide further insights in the mechanisms behind the improvement in cardiac function and clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.

    Article  PubMed  Google Scholar 

  2. Writing Committee M, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282–93.

    Google Scholar 

  3. Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.

    Article  PubMed  Google Scholar 

  4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

    Article  PubMed  Google Scholar 

  5. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–68.

    Article  CAS  PubMed  Google Scholar 

  6. Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639–53.

    Article  CAS  PubMed  Google Scholar 

  7. Ibrahim NE, Januzzi JL Jr. Beyond natriuretic peptides for diagnosis and Management of Heart Failure. Clin Chem. 2017;63(1):211–22.

    Article  CAS  PubMed  Google Scholar 

  8. Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T, et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002;71(23):2701–12.

    Article  CAS  PubMed  Google Scholar 

  9. McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.

    Article  PubMed  CAS  Google Scholar 

  10. Mangiafico S, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34(12):886–893c.

    Article  CAS  PubMed  Google Scholar 

  11. Gu J, Noe A, Chandra P, al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–14.

    Article  CAS  PubMed  Google Scholar 

  12. Menendez JT. The mechanism of action of LCZ696. Card Fail Rev. 2016;2(1):40–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102(17):1342–7.

    Article  CAS  PubMed  Google Scholar 

  14. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195–203.

    Article  CAS  PubMed  Google Scholar 

  15. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89–94.

    Article  PubMed  Google Scholar 

  16. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332(6159):78–81.

    Article  CAS  PubMed  Google Scholar 

  17. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87(2):464–9.

    Article  CAS  PubMed  Google Scholar 

  18. Ackermann DM, et al. Atrial natriuretic peptide: localization in the human heart. JAMA. 1986;256(8):1048.

    Article  CAS  PubMed  Google Scholar 

  19. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem. 2011;57(6):864–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC, Francis GS, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10(5 Suppl 3):1–30.

    Article  CAS  PubMed  Google Scholar 

  21. Heublein DM, Clavell AL, Stingo AJ, Lerman A, Wold L, Burnett JC Jr. C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells. Peptides. 1992;13(5):1017–9.

    Article  CAS  PubMed  Google Scholar 

  22. Cataliotti A, Giordano M, de Pascale E, Giordano G, Castellino P, Jougasaki M, et al. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol Renal Physiol. 2002;283(3):F464–72.

    Article  CAS  PubMed  Google Scholar 

  23. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87(4):1402–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2005;288(5):R1093–7.

    Article  CAS  PubMed  Google Scholar 

  25. Chauhan SD, Hobbs AJ, Ahluwalia A. C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarising factor. Int J Biochem Cell Biol. 2004;36(10):1878–81.

    Article  CAS  PubMed  Google Scholar 

  26. Moyes AJ, Hobbs AJ. C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci. 2019;20(9):2281

  27. Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015;13(9):1017–30.

    Article  CAS  PubMed  Google Scholar 

  28. Nakao K, et al. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens. 1992;10(9):907–12.

    Article  CAS  PubMed  Google Scholar 

  29. Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004;99(2):76–82.

    Article  CAS  PubMed  Google Scholar 

  30. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005;112(6):836–40.

    Article  CAS  PubMed  Google Scholar 

  31. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278(11):1808–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol. 2000;167(2):239–46.

    Article  CAS  PubMed  Google Scholar 

  33. Charles CJ, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Phys. 1996;271(2 Pt 2):R373–80.

    CAS  Google Scholar 

  34. Ng LL, et al. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond). 2004;106(2):129–33.

    Article  CAS  Google Scholar 

  35. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR. Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem. 2007;53(11):1928–35.

    Article  CAS  PubMed  Google Scholar 

  36. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46(4):610–20.

    Article  CAS  PubMed  Google Scholar 

  37. Maisel AS, Daniels LB, Anand IS, McCullough PA, Chow SL. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. Postgrad Med. 2018;130(3):299–307.

    Article  PubMed  Google Scholar 

  38. Chen HH. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both. J Am Coll Cardiol. 2007;49(10):1089–91.

    Article  PubMed  Google Scholar 

  39. Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005;102(48):17442–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1(4):258–64.

    Article  CAS  PubMed  Google Scholar 

  41. Miller WL, Phelps MA, Wood CM, Schellenberger U, van le A, Perichon R, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4(3):355–60.

    Article  CAS  PubMed  Google Scholar 

  42. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002;316(1–2):129–35.

    Article  CAS  PubMed  Google Scholar 

  43. Liang F, O’Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49(10):1071–8.

    Article  CAS  PubMed  Google Scholar 

  44. Diez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017;19(2):167–76.

    Article  CAS  PubMed  Google Scholar 

  45. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007;49(10):1079–88.

    Article  CAS  PubMed  Google Scholar 

  46. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(Pt 1):83–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrügg HR, Bartunek J, et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation. 2002;105(3):286–9.

    Article  CAS  PubMed  Google Scholar 

  48. McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999;8(1):79–84.

    Article  CAS  PubMed  Google Scholar 

  49. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet. 1998;351(9116):1657–8.

    Article  CAS  PubMed  Google Scholar 

  50. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999;17(1):S37–43.

    CAS  PubMed  Google Scholar 

  51. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–95.

    Article  CAS  PubMed  Google Scholar 

  52. •• Packer M, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61 Large scale study from surviving patients enrolled in the PARADIGM-HF trial comparing BNP, NT-proBNP, and urinary cGMP levels in the ARNI versus enalapril treatment group.

    Article  CAS  PubMed  Google Scholar 

  53. Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73(11):1273–84.

    Article  CAS  PubMed  Google Scholar 

  54. Nougue H, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598–605.

    Article  CAS  PubMed  Google Scholar 

  55. Velazquez EJ, Morrow DA, DeVore A, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48.

    Article  CAS  PubMed  Google Scholar 

  56. •• Januzzi JL, Jr., Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085-1095. Exploratory study of HFrEF patients treated with ARNI therapy showing a correlation between NT-proBNP reduction and reverse cardiac remodeling.

  57. • Myhre PL, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73(11):1264–72 Study investigating the prognostic performance of BNP measurements compared to NT-proBNP in a subset of HFrEF patients from the PARADIGM-HF trial started on ARNI therapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Ibrahim NE, Januzzi JL. Monitoring biomarkers in patients receiving Neprilysin inhibitors. Current Emergency and Hospital Medicine Reports. 2018;6(1):8–16.

    Article  Google Scholar 

  59. Norman JA, Little D, Bolgar M, di Donato G. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun. 1991;175(1):22–30.

    Article  CAS  PubMed  Google Scholar 

  60. Jaffe AS, Apple FS, Mebazaa A, Vodovar N. Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients. Clin Chem. 2015;61(8):1016–8.

    Article  CAS  PubMed  Google Scholar 

  61. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of markers of cardiac damage. Clin Chem. 2008;54(3):619–21.

    Article  CAS  PubMed  Google Scholar 

  62. Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther. 2016;34(4):191–8.

    Article  CAS  PubMed  Google Scholar 

  63. Pankow K, Schwiebs A, Becker M, Siems WE, Krause G, Walther T. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol. 2009;393(2):496–503.

    Article  CAS  PubMed  Google Scholar 

  64. D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017;19(6):710–7.

    Article  PubMed  CAS  Google Scholar 

  65. Yancy CW, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71(2):201–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Nestor Vasquez

  2. Department of Internal Medicine Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Spencer Carter & Justin L. Grodin

Authors
  1. Nestor Vasquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Spencer Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Justin L. Grodin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justin L. Grodin.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Biomarkers of Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vasquez, N., Carter, S. & Grodin, J.L. Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis. Curr Heart Fail Rep 17, 67–76 (2020). https://doi.org/10.1007/s11897-020-00458-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-020-00458-y

Keywords

Search

Navigation